- Recommendation ID
- TA275/1
- Question
During this appraisal it was noted that there is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents.
- Any explanatory notes
(if applicable)
Source guidance details
- Comes from guidance
- Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
- Number
- TA275
- Date issued
- February 2013
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 31/07/2021 |